Abstract
This research presents the impact assessment for medication price regulation policy in Colombia, having as a frame of reference the relevant markets and the Unique Code of Medicines (CUM) [Código Único de Medicamentos], regulated in the circulars 04, 05, 06, 07 of 2013, and 01 of 2014. After an interdisciplinary construction of a database with information between 2010 and 2017, a statistical model of dynamic difference-in-differences was estimated. Although the effect is momentary, the reduction of spending, as an objective of the policy, it is notorious. This behavior mainly occurs since most of the medicines included in regulation reflect monopoly prices, where the most significant reduction in prices was observed and, therefore, the most considerable expense restraint.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
